AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
potassium sulfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5485 | 7778-80-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Potassium sulfate is used to cleanse the colon (bowel) before colonoscopy in combination with sodium sulfate and magnesium sulfate.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 61 | |||
| kinase-selectivity-class | ACVR2B,AURKA,AXL,BMX,BRAF,CDK1,CDK4,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,IRAK1,IRAK3,JAK2,MAP2K6,MAPK7,PIK3CD,PIK3CG,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 27 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 22, 2021 | PMDA | NIHON PHARMACEUTICAL CO., LTD. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product dose omission issue | 42.33 | 17.34 | 53 | 3306 | 291634 | 90333454 |
| Diarrhoea | 18.41 | 17.34 | 76 | 3283 | 939114 | 89685974 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Testicular haemorrhage | 26.26 | 22.26 | 5 | 1599 | 252 | 42619479 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product dose omission issue | 45.01 | 18.52 | 57 | 3982 | 321725 | 110263535 |
| Therapeutic reaction time decreased | 33.69 | 18.52 | 11 | 4028 | 5268 | 110579992 |
| Testicular haemorrhage | 26.48 | 18.52 | 5 | 4034 | 248 | 110585012 |
| Diarrhoea | 22.12 | 18.52 | 91 | 3948 | 1139414 | 109445846 |
| Penile haemorrhage | 20.12 | 18.52 | 5 | 4034 | 903 | 110584357 |
| Groin infection | 19.30 | 18.52 | 5 | 4034 | 1065 | 110584195 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Bowel and colon cleansing preparation for colonoscopy | indication | 225106003 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT | SUPREP BOWEL PREP KIT | AZURITY | N022372 | Aug. 5, 2010 | RX | SOLUTION | ORAL | Aug. 5, 2027 | FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| CHEBI:32036 | CHEBI |
| CHEMBL2021424 | ChEMBL_ID |
| C031512 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB14499 | DRUGBANK_ID |
| 494961000221105 | SNOMEDCT_US |
| 4017690 | VANDF |
| 4019184 | VANDF |
| C0071780 | UMLSCUI |
| SO4 | PDB_CHEM_ID |
| SOH | PDB_CHEM_ID |
| SUL | PDB_CHEM_ID |
| 24507 | PUBCHEM_CID |
| 27516 | MMSL |
| NOCODE | MMSL |
| d07690 | MMSL |
| 006117 | NDDF |
| 1K573LC5TV | UNII |
| 34323 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Kali sulphuricum | HUMAN OTC DRUG LABEL | 1 | 0220-2979 | PELLET | 1 [hp_M] | ORAL | unapproved medical gas | 9 sections |
| SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE | Human Prescription Drug Label | 3 | 10572-012 | SOLUTION, CONCENTRATE | 3.13 g | ORAL | NDA | 28 sections |
| SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE | Human Prescription Drug Label | 3 | 10572-112 | SOLUTION, CONCENTRATE | 2.35 g | ORAL | NDA | 28 sections |
| SUPREP Bowel Prep | Human Prescription Drug Label | 3 | 24338-175 | SOLUTION, CONCENTRATE | 3.13 g | ORAL | NDA | 27 sections |
| SUPREP Bowel Prep | Human Prescription Drug Label | 3 | 24338-177 | SOLUTION, CONCENTRATE | 2.35 g | ORAL | NDA | 27 sections |
| Sodium sulfate, potassium sulfate and magnesium sulfate | HUMAN PRESCRIPTION DRUG LABEL | 3 | 31722-098 | SOLUTION | 3.13 g | ORAL | ANDA | 26 sections |
| SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 3 | 40032-700 | SOLUTION | 3.13 g | ORAL | ANDA | 25 sections |
| SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 3 | 43386-700 | SOLUTION | 3.13 g | ORAL | ANDA | 17 sections |
| Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Bowel Prep kit | HUMAN PRESCRIPTION DRUG LABEL | 3 | 51672-4170 | SOLUTION | 3.13 g | ORAL | ANDA | 32 sections |
| SUPREP Bowel Prep | Human Prescription Drug Label | 3 | 52268-012 | SOLUTION, CONCENTRATE | 3.13 g | ORAL | NDA | 28 sections |
| SUPREP Bowel Prep | Human Prescription Drug Label | 3 | 52268-112 | SOLUTION, CONCENTRATE | 2.35 g | ORAL | NDA | 28 sections |
| SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE | Human Prescription Drug Label | 3 | 52536-175 | SOLUTION, CONCENTRATE | 3.13 g | ORAL | NDA | 28 sections |
| SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE | Human Prescription Drug Label | 3 | 52536-177 | SOLUTION, CONCENTRATE | 2.35 g | ORAL | NDA | 28 sections |
| Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral | HUMAN PRESCRIPTION DRUG LABEL | 3 | 64380-116 | SOLUTION | 3.13 g | ORAL | ANDA | 26 sections |
| Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate | Human Prescription Drug Label | 3 | 67877-725 | SOLUTION | 3.13 g | ORAL | ANDA | 25 sections |
| sodium sulfate, potassium sulfate, and magnesium sulfate | HUMAN PRESCRIPTION DRUG LABEL | 3 | 69452-428 | SOLUTION | 3.13 g | ORAL | ANDA | 31 sections |
| Sodium sulfate, potassium sulfate and magnesium sulfate | HUMAN PRESCRIPTION DRUG LABEL | 3 | 72603-278 | SOLUTION | 3.13 g | ORAL | ANDA | 26 sections |